Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 7.52, based on a calculated equity value of RMB 634 billion [2][9][5]. Core Insights - The company reported a revenue of RMB 20.75 billion for 2024, reflecting a year-on-year growth of 6%. The net profit attributable to the parent company was RMB 3.57 billion, up 5.3% year-on-year. The company has a strong focus on shareholder returns, with a dividend payout of RMB 2.75 billion and a dividend yield of 6% [8][9]. - The product structure has improved, with significant growth in high-end products, particularly the "Zhuo Rui" brand, which saw sales increase by over 60%. The company is also diversifying its product offerings to drive revenue growth [8][9]. - The gross margin improved to 66.3%, benefiting from lower raw milk prices and enhanced product structure, although the net margin slightly decreased to 17.2% due to reduced government subsidies [8][9]. Financial Summary - Revenue projections for 2025-2027 are RMB 21.61 billion, RMB 22.99 billion, and RMB 24.31 billion, respectively, with growth rates of 4.1%, 6.4%, and 5.7% [4]. - The company's earnings per share (EPS) are forecasted to be RMB 0.44, RMB 0.47, and RMB 0.51 for 2025, 2026, and 2027, respectively [4][9]. - The company’s financial ratios indicate a gross margin of 67.1% in 2025, a net margin of 18.6%, and a return on equity (ROE) of 13.6% [4][8].

Investment Rating - The report maintains an "Outperform" rating for the company [2][7]. Core Views - The maternity subsidy policy is expected to strengthen domestic demand for infant formula, leading to a recovery in sales [3][11]. - The company plans to invest 1.2 billion yuan in a nationwide birth subsidy program starting in April 2025, providing monthly subsidies of one can of infant formula for five months to new mothers [3][11]. - The new product Zhuo Rui has significantly outperformed older products, becoming the company's largest single product, with sales increasing over 60% year-on-year [4][12]. Financial Performance - The company achieved a revenue of 20.749 billion yuan in 2024, a year-on-year increase of 6.2%, with a net profit of 3.570 billion yuan, up 5.3% [4][12]. - The gross profit margin for 2024 was 66.3%, an increase of 1.5 percentage points year-on-year, attributed to reduced price promotions and lower raw material costs [5][13]. - The payout ratio for dividends was approximately 76% in 2024, with expectations for continued growth in absolute dividend amounts [6][14]. Earnings Forecast - Revenue projections for 2025-2027 are set at 22.11 billion, 23.75 billion, and 25.50 billion yuan, respectively, with corresponding net profits of 3.96 billion, 4.34 billion, and 4.65 billion yuan [7][15]. - The expected earnings per share (EPS) for 2025-2027 are 0.44, 0.48, and 0.51 yuan, respectively [7][15]. - The target price for the stock is set at HK$7.00, based on a price-to-earnings (P/E) ratio of 15 for 2025 [2][15].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [10]. Core Insights - The company has demonstrated steady revenue and profit growth, with a slight underperformance in profit growth due to reduced government subsidies. In 2024, the company's revenue and net profit attributable to shareholders were CNY 20.749 billion and CNY 3.570 billion, respectively, reflecting year-on-year increases of 6.23% and 5.31% [6]. - The company is focusing on upgrading its product structure and is committed to a full lifecycle layout in its offerings. The revenue from infant formula, other dairy products, and nutritional supplements in 2024 was CNY 19.062 billion, CNY 1.514 billion, and CNY 0.173 billion, respectively, with year-on-year growth rates of 6.63%, 6.35%, and -25.37% [7]. - The company is effectively developing both online and offline channels, with over 77.1% of sales coming from offline channels. In 2024, the company held over 920,000 offline events, achieving a conversion rate of 28% for its "Mom's Love" initiative [8]. Financial Performance Summary - The company's revenue is projected to grow from CNY 22.020 billion in 2025 to CNY 24.300 billion in 2027, with corresponding earnings per share (EPS) expected to rise from CNY 0.43 to CNY 0.50 during the same period. The current stock price corresponds to price-to-earnings (PE) ratios of 14, 13, and 12 for the years 2025, 2026, and 2027, respectively [10]. - The gross profit margin for 2024 is reported at 66.34%, an increase of 1.51 percentage points year-on-year, while the net profit margin is at 17.61%, up by 0.77 percentage points [6].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [10]. Core Insights - The company has demonstrated steady revenue and profit growth, with a slight underperformance in profit growth due to reduced government subsidies. In 2024, the company's revenue and net profit attributable to shareholders were 20.749 billion and 3.570 billion yuan, respectively, reflecting year-on-year increases of 6.23% and 5.31% [6]. - The company is focusing on upgrading its product structure and expanding its lifecycle nutrition product offerings, with significant growth in infant formula and other dairy products [7]. - The company is effectively developing both online and offline channels, with a strong push into overseas markets, including Canada and Southeast Asian countries [8][9]. - The company anticipates growth driven by new fertility policies and aims to create a comprehensive ecosystem for nutrition products [10]. Financial Summary - For 2024, the company reported a gross margin of 66.34% and a net profit margin of 17.61%, with respective year-on-year increases of 1.51 and 0.77 percentage points [6]. - Revenue projections for 2025-2027 are 22.020 billion, 23.198 billion, and 24.300 billion yuan, with corresponding EPS of 0.43, 0.46, and 0.50 yuan [10]. - The company’s financial metrics indicate a stable growth trajectory, with a projected ROE of around 13.8% for 2025 [12].

着"价值链重构"。 DeepSeek在全球AI界引起轰动，动画电影《哪吒之魔童闹海》刷新全球动画票房记录…… 2025年以来，中国创新的多点突破引发国际社会广泛关注。近日，路透社、美联社等国际权 威媒体刊发评论文章聚焦中国创新力量，特别指出乳业领军企业飞鹤凭借连续四年蝉联婴幼儿 配 方 奶 粉 全 球 销 量 榜 首 的 成 绩 ， 刷 新 了 世 界 对 中 国 品 质 的 认 知 ， 上 演 了 中 国 制 造 又 一"DeepSeek时刻"。 美国东部时间4月4日-4月6日，第28届哈佛中国论坛在哈佛大学举行，飞鹤作为全球乳业标杆 企业亮相，成为全球媒体关注的焦点。作为海外学生组织中历史最悠久、规模最大的中国峰 会，本届哈佛中国论坛汇聚澳大利亚前总理陆克文、英伟达业务运营副总裁、美国科学院院士 罗伯特·温斯罗普等全球政、商、学界顶尖领袖，飞鹤董事长冷友斌受邀成为开幕式嘉宾，向 世界分享了中国乳业从"跟跑"到"领跑"的全球化发展思考。冷友斌在现场以飞鹤的跨越式成长 为例，向世界分享了探讨如何通过科技创新、品质提升和国际合作赋能企业发展，为全球行业 的高质量发展贡献智慧。 凭借过硬的品质和领先技术，飞鹤奶粉 ...

Investment Rating - The investment rating for China Feihe (06186.HK) is "Outperform" (maintained) [1] Core Views - The company achieved revenue of 20.749 billion RMB in 2024, a year-on-year increase of 6.2%, and a net profit of 3.570 billion RMB, up 5.3% year-on-year. The company plans to distribute a dividend of 0.3264 HKD per share, with a payout ratio of approximately 76%, enhancing shareholder returns [3][4] - The company is a leader in the Chinese infant formula market, with a continuous increase in market share and solid brand and channel advantages. The forecast for net profit in 2025-2026 has been slightly lowered due to intense market competition and delayed effects of fertility policies [3][4] Financial Summary and Valuation Indicators - Revenue and net profit projections for the upcoming years are as follows: - 2025E Revenue: 22.234 billion RMB, YOY +7.2% - 2025E Net Profit: 3.868 billion RMB, YOY +8.4% - 2026E Revenue: 23.669 billion RMB, YOY +6.5% - 2026E Net Profit: 4.139 billion RMB, YOY +7.0% - 2027E Revenue: 25.208 billion RMB, YOY +6.5% - 2027E Net Profit: 4.416 billion RMB, YOY +6.7% [5] - The projected EPS for 2025, 2026, and 2027 are 0.43, 0.46, and 0.49 RMB respectively, with corresponding P/E ratios of 12.8, 11.9, and 11.2 times [5] Product and Growth Strategy - The company is focusing on high-end and ultra-high-end products, with the "Star Feifan Zhuorui" series gaining market share. The birth rate in China is expected to improve, with 9.54 million births in 2024, a 5.8% increase year-on-year, which may drive demand for infant formula in 2025 [4] - The company is implementing a full-age nutrition strategy, covering all life stages from infants to the elderly, which is expected to support sustainable growth [4]

Investment Rating - The investment rating for China Feihe (06186.HK) is "Outperform" (maintained) [1] Core Views - The company achieved revenue of 20.749 billion RMB in 2024, a year-on-year increase of 6.2%, and a net profit of 3.570 billion RMB, up 5.3% year-on-year. The company plans to distribute a dividend of 0.3264 HKD per share, with a payout ratio of approximately 76%, enhancing shareholder returns [3][4] - The company is a leader in the Chinese infant formula market, with a continuous increase in market share and solid brand and channel advantages. The forecast for net profit for 2025-2026 has been slightly adjusted downwards due to intense market competition and the delayed effects of fertility policies [3][4] Financial Performance Summary - In 2024, the revenue from infant formula, other dairy products, and nutritional supplements was 190.62 billion RMB (up 6.6%), 15.14 billion RMB (up 6.3%), and 1.73 billion RMB (down 25.4%) respectively. The company is focusing on high-end products, particularly the Xingfeifan Zhuorui series, which is expected to drive revenue growth [4] - The gross margin for 2024 was 66.3%, an increase of 1.5 percentage points year-on-year, primarily due to product structure optimization and a decrease in raw material costs. However, the net profit margin was slightly affected by increased expenses and reduced government subsidies [5] - The company expects to maintain a reasonable pricing strategy while optimizing its expense ratio, which is anticipated to enhance profitability in the future [5] Future Outlook - The company plans to launch more high-end products in the second half of 2025, which is expected to further drive performance growth and improve gross margins. The full-age nutrition strategy is being steadily implemented, covering the entire lifecycle from infants to the elderly [4][5]

Investment Rating - The report maintains a "Buy" rating for China Feihe (6186.HK) with a projected PE of 13, 12, and 12 times for the years 2025, 2026, and 2027 respectively, indicating a favorable outlook compared to the Hang Seng Index [5][7]. Core Insights - In 2024, China Feihe achieved a revenue of 20.749 billion yuan, representing a year-on-year increase of 6.23%, and a net profit attributable to shareholders of 3.570 billion yuan, up 5.31% [1][2]. - The company plans to distribute a final dividend of 0.1632 HKD per share, totaling approximately 2.72 billion yuan, with a payout ratio of about 76.19% [1]. - The infant formula segment showed steady recovery with revenues of 19.062 billion yuan, reflecting a growth of 6.63% year-on-year [2]. Revenue Breakdown - Offline and online revenues for 2024 were 15.997 billion yuan and 4.751 billion yuan, respectively, with year-on-year growth rates of 2.89% and 19.25% [2]. - The company reported revenues from its infant formula business in mainland China, the United States, and Canada of 20.546 billion yuan, 164 million yuan, and 39 million yuan, respectively, with growth rates of 6.52%, -20.61%, and 1.90% [2]. Production Capacity and Margins - By the end of 2024, the company's production capacity increased to over 365,000 tons, marking an annual growth of over 11.62% [2]. - The gross margin improved to 66.34%, up 1.51 percentage points year-on-year, primarily due to a 15% decrease in raw milk prices and product mix upgrades [2][3]. Profitability Metrics - The net profit margin for 2024 was 17.21%, a slight decrease of 0.15 percentage points year-on-year, attributed to reduced government subsidies and increased minority interest losses [3]. - Management expenses decreased, with the management expense ratio at 8.10%, down 0.92 percentage points year-on-year [3]. Market Outlook - The infant formula market is expected to stabilize gradually, supported by newborn support measures, with China Feihe positioned as a leading player due to its strong R&D capabilities and brand recognition [4]. - The high-end infant formula segment is anticipated to drive continued growth, supported by rising disposable income and demand for premium products [4].

Investment Rating - The report maintains a "Buy" rating for China Feihe (6186.HK) with a target price of HKD 6.65, indicating a potential upside of 13.3% from the current price of HKD 5.87 [3][6]. Core Views - China Feihe's net profit for 2H24 fell short of market expectations due to short-term inventory clearance in functional nutrition products, including adult milk powder, which affected overall gross margin performance. However, the infant formula business showed revenue growth in line with expectations, and profit margins remained robust. Management is confident that revenue growth in 2025 will exceed that of 2024, with a slight increase in gross margin expected year-on-year [1][6]. - As a leader in the infant formula market, China Feihe is expected to continue driving industry consolidation. The company is actively investing in brand marketing and product technology development to enhance brand strength and meet consumer demands with higher-end products [1][6]. Summary by Sections Financial Performance - For 2023, the company reported revenue of RMB 19,532 million, with a year-on-year decline of 8.3%. In 2024, revenue is expected to increase by 6.2% to RMB 20,749 million, and further growth is projected for 2025 with an estimated revenue of RMB 21,817 million, reflecting a 5.1% increase [8][10]. - The net profit for 2023 was RMB 3,390 million, down 31.4% year-on-year, but is expected to recover with a 5.3% increase in 2024 to RMB 3,570 million and a further 10.5% increase in 2025 to RMB 3,944 million [8][10]. Product Strategy - The company is focusing on high-end product offerings, with ultra-high-end products seeing a revenue increase of 17% in 2024, accounting for 69% of total revenue. The management anticipates continued growth in this segment, particularly for the Zhuorui brand, which has become the largest revenue contributor [6][11]. - A RMB 12 billion maternity subsidy plan is set to launch in April 2025, expected to have a limited negative impact on overall profit margins due to its structure and the company's marketing adjustments [6][11]. Dividend Policy - China Feihe plans to increase its dividend payout, with a projected dividend of HKD 0.3264 per share for 2024, raising the payout ratio to 76.1%. The management aims for a 10% annual increase in absolute dividend amounts over the next two years, assuming no major acquisitions [6][11].

Investment Rating - The report maintains a "Buy" rating for China Feihe (6186.HK) with a target price of HKD 6.65, indicating a potential upside of 13.3% from the current price of HKD 5.87 [3][6]. Core Insights - China Feihe's net profit for 2H24 fell short of market expectations due to short-term inventory clearance in functional nutrition products, including adult milk powder, which affected overall gross margin performance. However, the infant formula business showed revenue growth in line with expectations, and profit margins remained robust. Management is confident that revenue growth in 2025 will exceed that of 2024, with a slight increase in gross margin expected year-on-year [1][6]. - The company is positioned as a leader in the infant formula market, driving industry consolidation trends. The report suggests that Feihe will continue to capture market share through increased brand investment and product innovation [1][6]. Financial Performance and Projections - Revenue for 2023 was reported at RMB 19,532 million, with a projected increase to RMB 20,749 million in 2024, reflecting a year-on-year growth of 6.2%. The forecast for 2025 anticipates revenue of RMB 21,817 million, representing a growth of 5.1% [8][11]. - The net profit for 2023 was RMB 3,390 million, with expectations of growth to RMB 3,570 million in 2024 and RMB 3,944 million in 2025, indicating a year-on-year increase of 5.3% and 10.5%, respectively [8][11]. - The gross margin is expected to improve from 64.8% in 2023 to 66.3% in 2024, with further stability projected for 2025 [8][11]. Market Position and Strategy - China Feihe is focusing on high-end product offerings, with ultra-high-end products expected to see a revenue increase of 17% in 2024, contributing to 69% of total revenue. The company plans to launch even higher-end products in 2H25 [6][11]. - The management has announced a RMB 12 billion maternity subsidy plan, which is expected to have a limited negative impact on profit margins, as the actual costs will be lower than the total subsidy amount [6][11]. Dividend Policy - The company has increased its dividend payout, with a projected dividend of HKD 0.3264 per share for 2024, raising the payout ratio to 76.1%. Management aims for a 10% annual increase in absolute dividend amounts over the next two years [6][11].